Lutathera for Meningioma

Phase-Based Progress Estimates
MeningiomaLutathera - Drug
All Sexes
What conditions do you have?

Study Summary

This trial will test whether Lutathera is effective in treating meningioma. Lutathera will be given intravenously every 8 weeks for 4 doses, and PET-MRI scans will be done before treatment and 6 months after the start of treatment.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 2 Years Post Treatment

12 months
Objective Response Rate (ORR)
Overall Survival at 12 months (OS-12)
2 Years Post Treatment
Overall Survival (OS)
Progression Free Survival (PFS)
6 Months
Progression Free Survival at 6 months (PFS-6)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

1 of 1

Experimental Treatment

32 Total Participants · 1 Treatment Group

Primary Treatment: Lutathera · No Placebo Group · Phase 2

Experimental Group · 1 Intervention: Lutathera · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years post treatment

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,264 Previous Clinical Trials
753,559 Total Patients Enrolled
1 Trials studying Meningioma
5 Patients Enrolled for Meningioma
Erik Sulman, MDPrincipal InvestigatorNew York Langone Health
1 Previous Clinical Trials
10 Total Patients Enrolled
Sylvia Kurz, MDPrincipal InvestigatorNYU Langone Health
2 Previous Clinical Trials
16 Total Patients Enrolled
Erik Sukman, MDPrincipal InvestigatorNew York Langone Health

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a measurable disease defined as at least one lesion measuring ≥10 mm in at least one dimension by contrast-enhanced MRI performed within 30 days prior to study registration.